Peroxisome proliferator-activated receptor-γ antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia

被引:24
作者
Collin, M [1 ]
Murch, O [1 ]
Thiemermann, C [1 ]
机构
[1] Queen Mary Univ London, St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Ctr Med Expt Nephrol & Crit Care, London E1 4NS, England
关键词
endotoxemia; preconditioning; peroxisome proliferator-activated receptor-gamma; GW9662; T0070907; parecoxib;
D O I
10.1097/01.CCM.0000206472.63040.6D
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective. There is evidence that a) ligands of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-gamma and b) lipopolysaccharide preconditioning protect the organs against the multiple organ injury and dysfunction caused by endotoxemia. Here we investigate the hypothesis that the protective effects of lipopolysaccharide preconditioning are due to an enhanced formation of endogenous ligands of PPAR-gamma. Design: Prospective, randomized study. Setting. University-based research laboratory. Subjects, Ninety-nine anesthetized male Wistar rats. Interventions. Rats were pretreated with low-dose lipopolysaccharide (1 mg/kg intraperitoneally, 24 hrs before induction of endotoxemia) in the absence or presence of the selective PPAR-gamma antagonists GW9662 (1 mg/kg intraperitoneally) or T0070907 (1 mg/kg intraperitoneally) or the selective cyclooxygenase-2 inhibitor parecoxib (20 mg/kg intraperitoneally). At 24 hrs after preconditioning with low-dose lipopolysaccharide, the rats were subjected to acute severe endotoxemia (lipopolysaccharide 6 mg/kg intravenously). Measurements and Main Results: Lipopolysaccharide preconditoning significantly attenuated the development of renal dysfunction (serum creatinine), hepatocellular injury (serum alanine aminotransferase and aspartate aminotransferase), and circulatory failure (hypotension) as well as the increase in the plasma levels of interleukin-1 beta caused by severe endotoxemia. All of these beneficial effects afforded by preconditioning with lipopolysaccharide were attenuated by the specific PPAR-gamma antagonists used. In contrast, the cyclooxygenase-2 inhibitor parecoxib did not affect the beneficial effects afforded by preconditioning with lipopolysaccharide. Conclusions. We propose that endogenous ligands of PPAR-gamma contribute to the protection afforded by lipopolysaccharide preconditioning against the organ injury and dysfunction associated with severe endotoxemia in the rat.
引用
收藏
页码:1131 / 1138
页数:8
相关论文
共 54 条
[1]   Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock [J].
Abdelrahman, M ;
Sivarajah, A ;
Thiemermann, C .
CARDIOVASCULAR RESEARCH, 2005, 65 (04) :772-781
[2]   The peroxisome proliferator-activated receptor-γ ligand 15-deoxyΔ12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock [J].
Abdelrahman, M ;
Collin, M ;
Thiemermann, C .
SHOCK, 2004, 22 (06) :555-561
[4]  
BAUE AE, 1993, PATHOPHYSIOLOGY SHOC, P1004
[5]   Endothelial expression of selectins during endotoxin preconditioning [J].
Bauer, P ;
Welbourne, T ;
Shigematsu, T ;
Russell, J ;
Granger, DN .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2000, 279 (06) :R2015-R2021
[6]   Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the litigation of PPARγ [J].
Bell-Parikh, LC ;
Ide, T ;
Lawson, JA ;
McNamara, P ;
Reilly, M ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (06) :945-955
[7]   The mechanisms of action of PPARs [J].
Berger, J ;
Moller, DE .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435
[9]   ENDOTOXIN PRETREATMENT INCREASES ENDOGENOUS MYOCARDIAL CATALASE ACTIVITY AND DECREASES ISCHEMIA REPERFUSION INJURY OF ISOLATED RAT HEARTS [J].
BROWN, JM ;
GROSSO, MA ;
TERADA, LS ;
WHITMAN, GJR ;
BANERJEE, A ;
WHITE, CW ;
HARKEN, AH ;
REPINE, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) :2516-2520
[10]   The cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 ameliorates ischemic acute renal failure [J].
Chatterjee, PK ;
Patel, NSA ;
Cuzzocrea, S ;
Brown, PAJ ;
Stewart, KN ;
Mota-Filipe, H ;
Britti, D ;
Eberhardt, W ;
Pfeilschifter, J ;
Thiemermann, C .
CARDIOVASCULAR RESEARCH, 2004, 61 (03) :630-643